These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 21756539)

  • 1. RITA enhances chemosensivity of pre-B ALL cells to doxorubicin by inducing p53-dependent apoptosis.
    Kazemi A; Safa M; Shahbazi A
    Hematology; 2011 Jul; 16(4):225-31. PubMed ID: 21756539
    [TBL] [Abstract][Full Text] [Related]  

  • 2. RITA inhibits multiple myeloma cell growth through induction of p53-mediated caspase-dependent apoptosis and synergistically enhances nutlin-induced cytotoxic responses.
    Saha MN; Jiang H; Mukai A; Chang H
    Mol Cancer Ther; 2010 Nov; 9(11):3041-51. PubMed ID: 21062913
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The p53-reactivating small-molecule RITA enhances cisplatin-induced cytotoxicity and apoptosis in head and neck cancer.
    Roh JL; Ko JH; Moon SJ; Ryu CH; Choi JY; Koch WM
    Cancer Lett; 2012 Dec; 325(1):35-41. PubMed ID: 22634494
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cyclic AMP-induced p53 destabilization is independent of EPAC in pre-B acute lymphoblastic leukemia cells in vitro.
    Safa M; Kazemi A; Zaker F; Razmkhah F
    J Recept Signal Transduct Res; 2011 Jun; 31(3):256-63. PubMed ID: 21619452
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cyclin-dependent kinase inhibitors sensitize tumor cells to nutlin-induced apoptosis: a potent drug combination.
    Cheok CF; Dey A; Lane DP
    Mol Cancer Res; 2007 Nov; 5(11):1133-45. PubMed ID: 18025259
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mouse double minute antagonist Nutlin-3a enhances chemotherapy-induced apoptosis in cancer cells with mutant p53 by activating E2F1.
    Ambrosini G; Sambol EB; Carvajal D; Vassilev LT; Singer S; Schwartz GK
    Oncogene; 2007 May; 26(24):3473-81. PubMed ID: 17146434
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dual targeting of wild-type and mutant p53 by small molecule RITA results in the inhibition of N-Myc and key survival oncogenes and kills neuroblastoma cells in vivo and in vitro.
    Burmakin M; Shi Y; Hedström E; Kogner P; Selivanova G
    Clin Cancer Res; 2013 Sep; 19(18):5092-103. PubMed ID: 23864164
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Novel MDM2 inhibitor SAR405838 (MI-773) induces p53-mediated apoptosis in neuroblastoma.
    Lu J; Guan S; Zhao Y; Yu Y; Wang Y; Shi Y; Mao X; Yang KL; Sun W; Xu X; Yi JS; Yang T; Yang J; Nuchtern JG
    Oncotarget; 2016 Dec; 7(50):82757-82769. PubMed ID: 27764791
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Inhibitory role of cAMP on doxorubicin-induced apoptosis in pre-B ALL cells through dephosphorylation of p53 serine residues.
    Safa M; Kazemi A; Zand H; Azarkeivan A; Zaker F; Hayat P
    Apoptosis; 2010 Feb; 15(2):196-203. PubMed ID: 19882354
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The MDM2 antagonist nutlin-3 sensitizes p53-null neuroblastoma cells to doxorubicin via E2F1 and TAp73.
    Peirce SK; Findley HW
    Int J Oncol; 2009 May; 34(5):1395-402. PubMed ID: 19360352
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Interferon-alpha enhances sensitivity of human osteosarcoma U2OS cells to doxorubicin by p53-dependent apoptosis.
    Yuan XW; Zhu XF; Huang XF; Sheng PY; He AS; Yang ZB; Deng R; Feng GK; Liao WM
    Acta Pharmacol Sin; 2007 Nov; 28(11):1835-41. PubMed ID: 17959036
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The telomerase inhibitor MST-312 synergistically enhances the apoptotic effect of doxorubicin in pre-B acute lymphoblastic leukemia cells.
    Ghasemimehr N; Farsinejad A; Mirzaee Khalilabadi R; Yazdani Z; Fatemi A
    Biomed Pharmacother; 2018 Oct; 106():1742-1750. PubMed ID: 30170357
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inhibition of telomerase using BIBR1532 enhances doxorubicin-induced apoptosis in pre-B acute lymphoblastic leukemia cells.
    Bashash D; Zareii M; Safaroghli-Azar A; Omrani MD; Ghaffari SH
    Hematology; 2017 Jul; 22(6):330-340. PubMed ID: 28054503
    [TBL] [Abstract][Full Text] [Related]  

  • 14. PI3K-δ inhibition using CAL-101 exerts apoptotic effects and increases doxorubicin-induced cell death in pre-B-acute lymphoblastic leukemia cells.
    Safaroghli-Azar A; Bashash D; Sadreazami P; Momeny M; Ghaffari SH
    Anticancer Drugs; 2017 Apr; 28(4):436-445. PubMed ID: 28125433
    [TBL] [Abstract][Full Text] [Related]  

  • 15. PTEN reverses MDM2-mediated chemotherapy resistance by interacting with p53 in acute lymphoblastic leukemia cells.
    Zhou M; Gu L; Findley HW; Jiang R; Woods WG
    Cancer Res; 2003 Oct; 63(19):6357-62. PubMed ID: 14559824
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Schedule-dependent synergy between the heat shock protein 90 inhibitor 17-(dimethylaminoethylamino)-17-demethoxygeldanamycin and doxorubicin restores apoptosis to p53-mutant lymphoma cell lines.
    Robles AI; Wright MH; Gandhi B; Feis SS; Hanigan CL; Wiestner A; Varticovski L
    Clin Cancer Res; 2006 Nov; 12(21):6547-56. PubMed ID: 17085670
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Targeting MDM2 by the small molecule RITA: towards the development of new multi-target drugs against cancer.
    Espinoza-Fonseca LM
    Theor Biol Med Model; 2005 Sep; 2():38. PubMed ID: 16174299
    [TBL] [Abstract][Full Text] [Related]  

  • 18. HIPK2 regulation by MDM2 determines tumor cell response to the p53-reactivating drugs nutlin-3 and RITA.
    Rinaldo C; Prodosmo A; Siepi F; Moncada A; Sacchi A; Selivanova G; Soddu S
    Cancer Res; 2009 Aug; 69(15):6241-8. PubMed ID: 19638586
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Therapeutic potential of Mdm2 inhibition in malignant germ cell tumours.
    Bauer S; Mühlenberg T; Leahy M; Hoiczyk M; Gauler T; Schuler M; Looijenga L
    Eur Urol; 2010 Apr; 57(4):679-87. PubMed ID: 19560254
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inhibition of tachykinin NK
    Bayati S; Bashash D; Ahmadian S; Safaroghli-Azar A; Alimoghaddam K; Ghavamzadeh A; Ghaffari SH
    Eur J Pharmacol; 2016 Nov; 791():274-283. PubMed ID: 27609608
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.